Latest Headlines

Latest Headlines

Resverlogix gets a $116M China drug development deal, stokes buyout buzz

Resverlogix has struck a deal to trade development rights in China for its lead cardio drug in exchange for a $41.5 million equity stake in the biotech along with up to $75 million in sales milestones. And today the Canadian biotech's CEO added a sweetener, telling Bloomberg that he's in talks with unnamed suitors to sell the company.

Eisai, Nihon Medi-Physics plan work on dementia with Lewy bodies

Eisai and Nihon Medi-Physics plan to work together on one of Japan's three major dementia types, termed "dementia with Lewy bodies," meaning abnormal massing of protein inside nerve cells. The research is part of a broad cascade of efforts around the globe into diagnostics and treatments for dementia-related studies.

Shenzhen Hepalink buys in to develop Resverlogix cardio candidate in China

Shenzhen Hepalink Pharmaceutical said it has reached an agreement to develop and commercialize in Greater China a cardiovascular candidate from Resverlogix Corp. in a deal that could even include wider territorial sales if successful.

Generex announces second medical marijuana outlicensing deal for its drug delivery tech

Generex's proprietary RapidMist buccal drug delivery device is finding a mark in the medical marijuana arena. The company announced its second medical marijuana outlicensing agreement, this time with Smoofi, a consultant to licensed U.S. medical and recreational marijuana operators and retail dispensaries.

Gilead plans Israel marketing office to remain with NewPharm drug chain

Gilead Sciences reportedly plans to open a marketing office in Israel where it sells its products through NewPharm, an Israel drug store chain.

China hopes to learn ins and outs of regulation from U.S. FDA

China's FDA is laying plans to work directly with its U.S. counterpart to learn the secrets of drug and medical-device regulation and bring China drug-making and other regulated industries up to international standards.

Device companies team up to launch Asia Pacific Medical Technology Association in Singapore

Industry bigwigs are teaming up to create the first medical device industry association focused solely on Asia. The member companies of the just-launched Asia Pacific Medical Technology Association include Abbott, Baxter, B. Braun, Becton Dickinson, Boston Scientific, Cardinal Health, GE Healthcare, Johnson & Johnson, Medtronic, Philips, Siemens, Stryker and Zimmer.

AstraZeneca lends its oncology star to Celgene and recruits Innate in a PD-L1 deal spree

AstraZeneca signed a pair of agreements centered on its most prized cancer therapy, selling a stake to the hematology experts at Celgene and buying the rights to a complementary treatment from Innate Pharma.

Juno and AstraZeneca pair two hot immunotherapies in new cancer study

Juno Therapeutics and AstraZeneca are joining forces to test their respective cancer treatments in tandem, combining newfangled therapies that promise to use the immune system to combat tumors.

U.S.-based Threshold revives NZ cancer candidate for resistant lung cancer

New Zealand research on a promising cancer drug that was discarded by previous companies was revived by U.S.-based Threshold Pharmaceuticals, which announced a promising showing in Phase I and II trials for treating a type of resistant lung cancer.